MiNK Therapeutics Reports Q1 2025 Progress and Financials

Mink Therapeutics, Inc. ( (INKT) ) has released its Q1 earnings. Here is a breakdown of the information Mink Therapeutics, Inc. presented to its investors.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company is known for its off-the-shelf iNKT platform, which aims to provide scalable and reproducible treatments.

In its first-quarter 2025 earnings report, MiNK Therapeutics highlighted significant clinical and strategic progress. The company reported advancements in its iNKT platform, particularly in cancer and immune-mediated diseases, and emphasized ongoing strategic discussions in oncology and immunology.

Key financial metrics from the report include a net loss of $2.8 million for the quarter, a reduction from the $3.8 million loss in the same period the previous year. The company also reported a cash balance of $3.2 million, with cash used in operations decreasing to $1.3 million from $2.5 million in the prior year. MiNK is actively enrolling patients in a Phase 2 gastric cancer trial and has shown promising clinical data in PD-1–resistant tumors.

The company is also pursuing broader patient access through clinical trials and compassionate use programs, with potential funding from NIAID for its GvHD program. These developments highlight MiNK’s strategic focus on expanding its reach in solid tumors and inflammatory diseases.

Looking ahead, MiNK Therapeutics is poised to enhance its liquidity through near-term capital transactions and strategic partnerships, which are expected to support the delivery of its iNKT therapies on a larger scale.